RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 SOF Plus GS-5816 Effective in Noncirrhotic, Treatment-Naïve Patients Infected with HCV Genotypes 1 to 6
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 17
OP 17
DO 10.1177/155989771448011
UL http://mdc.sagepub.com/content/14/48/17.1.abstract
AB The prowess of the nucleotide polymerase inhibitor sofosbuvir (SOF) against hepatitis C virus (HCV) is known. This article presents results from a study investigating a 12-week fixed-dose combination of SOF and nonstructural protein 5A (NS5A) inhibitor GS-5816 regimen in noncirrhotic, treatment-naïve HCV genotype 1 patients.